Sarepta Therapeutics Files DEF 14A on Executive Compensation
Ticker: SRPT · Form: DEF 14A · Filed: Apr 24, 2025 · CIK: 873303
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: SRPT
TL;DR
Sarepta's DEF 14A is out, showing exec pay details and equity award valuations for 2024.
AI Summary
Sarepta Therapeutics, Inc. filed a DEF 14A on April 24, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December 31, 2024. The filing includes information on stock awards and option awards granted to executives, such as Douglas Singram, and changes in the fair value of outstanding equity awards.
Why It Matters
This filing provides transparency into how Sarepta Therapeutics compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and corporate governance, not indicating immediate financial risk.
Key Numbers
- 20250424 — Filing Date (Date the DEF 14A was filed with the SEC.)
- 20250605 — Period of Report (The period the filing is reporting on.)
- 1231 — Fiscal Year End (Indicates the end of Sarepta's fiscal year.)
Key Players & Entities
- Sarepta Therapeutics, Inc. (company) — Filer
- Douglas Singram (person) — Executive mentioned in relation to compensation
- 0000873303 (company) — Central Index Key for Sarepta Therapeutics
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used to solicit shareholder votes on important corporate matters, such as the election of directors and executive compensation.
Who is Douglas Singram and what is his role in this filing?
Douglas Singram is an executive at Sarepta Therapeutics, and his name appears in relation to compensation details, specifically concerning stock awards and option awards.
What specific types of compensation are detailed in this filing?
The filing details executive compensation, including stock awards and option awards, and provides information on the fair value of these awards as of specific dates.
When was Sarepta Therapeutics, Inc. incorporated?
Sarepta Therapeutics, Inc. was incorporated in Delaware (DE).
What are the previous names of Sarepta Therapeutics, Inc.?
Sarepta Therapeutics, Inc. was formerly known as AVI BIOPHARMA INC and ANTIVIRALS INC, with name changes occurring in 1998 and 1997, respectively.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 by Douglas Singram regarding Sarepta Therapeutics, Inc. (SRPT).